Results 361 to 370 of about 556,132 (392)
Some of the next articles are maybe not open access.
Cyclosporine immunosuppression
American Journal of Health-System Pharmacy, 1984The chemistry, pharmacokinetics, mechanism of action, clinical efficacy in organ transplants, adverse effects, and dosage and administration of cyclosporine, a new immunosuppressant, are reviewed. Advice on counseling patients who take the drug is also included. Cyclosporine is a cyclic undecapeptide with a high molecular weight.
D M, Canafax, N L, Ascher
openaire +2 more sources
Transplantation, 2006
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Trends in Pharmacological Sciences, 1993
Experimental models of autoimmune diseases have demonstrated that such disease can be prevented or treated by selectively interfering with activation of any of these cell types: antigen-presenting cells, autoreactive T cells and regulatory T cells. Luciano Adorini and colleagues discuss these approaches to selective immunosuppression and examine how ...
L, Adorini +3 more
openaire +3 more sources
Experimental models of autoimmune diseases have demonstrated that such disease can be prevented or treated by selectively interfering with activation of any of these cell types: antigen-presenting cells, autoreactive T cells and regulatory T cells. Luciano Adorini and colleagues discuss these approaches to selective immunosuppression and examine how ...
L, Adorini +3 more
openaire +3 more sources
Current Opinion in Immunology, 1992
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?
Nature reviews: Gastroenterology & hepatology, 2022E. Villablanca, K. Selin, C. Hedin
semanticscholar +1 more source
Current Opinion in Organ Transplantation, 2012
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources
[Pharmacogenetics of immunosuppressants].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015Individualized drug therapy with immunosuppressants is an hot topic in transplantation. Therapeutic drug monitoring (TDM) is currently utilized to guide therapy, but toxic or subtherapeutic concentrations can only be identified after the drug is administered.
Cojutti P. G., Baraldo M.
openaire +3 more sources
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Nature Reviews Clinical Oncology, 2019Y. Togashi, K. Shitara, H. Nishikawa
semanticscholar +1 more source